Severe diastolic dysfunction (39% prevalence) in TAVI patients predicted higher mortality and heart failure admissions, linked to disrupted phospholipid and acylcarnitine metabolism.
What are the clinical characteristics and molecular mechanisms associated with severe diastolic dysfunction in patients with severe aortic stenosis undergoing TAVI?
In patients with severe aortic stenosis undergoing TAVI, severe diastolic dysfunction is associated with worse clinical outcomes and distinct molecular profiles involving altered energy metabolism, structural remodeling, and inflammation.
We aimed to better understand patient characteristics and pathophysiological mechanisms associated with severe diastolic dysfunction in aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI). Patients with severe aortic stenosis often have echocardiographic signs of diastolic dysfunction. However, their characteristics and underlying disease mechanisms remain unclear. Untargeted LC–MS lipidomics (1110 lipids) and proteomics (834 proteins) were performed on peri-procedural plasma from 231 TAVI patients. Pre-procedural echocardiography was available in 191 patients. DIABLO (mixOmics, version 6.3.0, R version 4.4.1) was used to integrate lipidomic and proteomic profiles. Median age was 80 years, and 61% were female. In total, 75 (39%) patients had severe diastolic dysfunction. Patients with severe diastolic dysfunction more often had atrial fibrillation, higher plasma NT-proBNP concentrations, and more heart failure hospitalizations and mortality. Multi-omic network analysis identified two major lipid–protein clusters associated with severe diastolic dysfunction. The first showed dysregulation of membrane phospholipids such as cardiolipins (essential for mitochondrial integrity and energy metabolism), and phosphatidylserines (cytoprotective and anti-inflammatory properties). This cluster was associated with cytoskeletal and extracellular matrix remodeling. The second cluster showed high concentrations of acylcarnitines (indicative of metabolic dysfunction), which were associated with extracellular matrix remodeling and inflammatory responses. In patients with aortic stenosis undergoing TAVI, those with severe diastolic dysfunction showed a disrupted balance of membrane phospholipids and acylcarnitines, suggesting that impaired energy metabolism, cellular and extracellular structural remodeling, and inflammatory responses may underlie the development and progression of diastolic dysfunction and heart failure. We investigated clinical features and molecular profiles linked to severe diastolic dysfunction in aortic stenosis patients undergoing TAVI. Untargeted lipidomics (1110 lipids) and proteomics (834 proteins) were performed on peri-procedural plasma from 231 patients. Pre-procedural echocardiography was available in 191 patients. Severe diastolic dysfunction was present in 39% and was associated with atrial fibrillation, higher NT-proBNP, and more heart failure hospitalizations and mortality. Multi-omic integration identified two major lipid-protein clusters. The first was characterized by dysregulated membrane phospholipids, including cardiolipins and phosphatidylserines, linked to cytoskeletal and extracellular matrix remodeling. The other showed elevated acylcarnitines, indicating metabolic dysfunction, and inflammatory activation. These findings suggest that altered energy metabolism, structural remodeling, and inflammation are associated with severe diastolic dysfunction in aortic stenosis. Patients with severe aortic stenosis and severe diastolic dysfunction undergoing TAVI (n = 75 patients with severe diastolic dysfunction, n = 116 patients without severe diastolic dysfunction) show a disrupted balance of membrane phospholipids and acylcarnitines, suggesting that impaired energy metabolism, cellular and extracellular structural remodeling, and inflammatory responses may underlie the development and progression of diastolic dysfunction and heart failure. TAVI = transcatheter aortic valve replacement; LAVI = left atrial volume index; PASP = pulmonary artery systolic pressure; LA = left atrium; GLS = global longitudinal strain; LVMI = left ventricular mass index. • Diastolic dysfunction was linked to more atrial fibrillation and higher NT-proBNP. • Diastolic dysfunction predicted more HF admissions and mortality after TAVI. • Diastolic dysfunction was linked to altered phospholipid and acylcarnitine balance. • Metabolic impairments and inflammation may drive diastolic dysfunction in AS. • These mechanisms mirror those in heart failure with preserved ejection fraction.
Panaou et al. (2026) studied this question. Severe diastolic dysfunction (39% prevalence) in TAVI patients predicted higher mortality and heart failure admissions, linked to disrupted phospholipid and acylcarnitine metabolism.